The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Tissue‐specific mtDNA lesions and radical‐associated mitochondrial dysfunction in human hearts exposed to doxorubicin
Abstract
Doxorubicin causes a chronic cardiomyopathy. Although the exact pathogenesis is unknown, recent animal data suggest that somatically acquired alterations of mitochondrial DNA (mtDNA) and concomitant mitochondrial dysfunction play an important role in its onset. In this study, skeletal and myocardial muscles were examined from human autopsies. Compared to controls ( n = 8), doxorubicin‐exposed hearts ( n = 6) showed low absolute enzyme activity of mtDNA‐encoded nicotinamide adenine dinucleotide hydrogen dehydrogenase (NADH DH, 79% residual activity, p = 0.03) and cytochrome c oxidase (COX, 59% residual activity, p < 0.001), but not of succinate dehydrogenase (SDH), which is encoded exclusively by nuclear DNA. NADH DH/SDH and COX/SDH ratios were 37% ( p < 0.001) and 27% ( p < 0.001) of controls. Expression of the mtDNA‐encoded subunit II of COX was reduced (82%, p = 0.04), compared to its unchanged nucleus‐encoded subunit IV. MtDNA‐content was diminished (56%, p = 0.02), but the ‘common’ mtDNA‐deletion was increased (9.2‐fold, p = 0.004). Doxorubicin‐exposed hearts harboured numerous additional mtDNA rearrangements lacking direct repeats. They contained elevated levels of malondialdehyde (MDA) ( p = 0.006, compared to controls), which correlated inversely with the COX/SDH ratio ( r = −0.45, p = 0.02) and the mtDNA‐content ( r = −0.75, p = 0.002), and correlated positively with the levels of the ‘common’ deletion ( r = 0.80, p < 0.001). Doxorubicin‐exposed hearts also contained the highest levels of superoxide ( p < 0.001, compared to controls), which correlated negatively with the mtDNA‐encoded respiratory chain activities, such as the COX/SDH ratio ( r = −0.57, p = 0.02) and the NADH/SDH ratio ( r = −0.52, p = 0.04), as well as with the mtDNA content ( r = −0.69, p = 0.003), and correlated positively with the frequency of the ‘common’ deletion ( r = 0.76, p < 0.001) and the MDA levels ( r = 0.86, p < 0.001). Doxorubicin‐exposed hearts contained electron‐dense deposits within mitochondria. Hearts exposed to other anthracyclines ( n = 6) or skeletal muscle (all groups) had no mitochondrial dysfunction. Doxorubicin, unlike other anthracyclines, augments lipid peroxidation, induces mtDNA mutations and decreases mtDNA content in human hearts. These lesions have an impact on mitochondrial function and could be of importance in the pathogenesis of clinical cardiomyopathy. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing
Trounce, I., Byrne, E., & Marzuki, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92143-0 · Cited by 730
Progressive Increase of the Mutated Mitochondrial DNA Fraction in Kearns-Sayre Syndrome
Larsson, N.-G., Holme, E., Kristiansson, B., Oldfors, A., & Tulinius, M. (1990) · Pediatric Research · doi:10.1203/00006450-199008000-00011 · Cited by 324
Corral-Debrinski, M. (1991) · JAMA · doi:10.1001/jama.1991.03470130092035 · Cited by 1 · cited 1×
“Our hypothesis hinges on the fact that mtDNA damage leads to respiratory chain dysfunction, which can subsequently generate free radicals, which then, in turn, may either attack the respiratory chain itself or consecutively damage mtDNA [7,8].”
Background
Research works printed but not linked: 38
- 10.1056/NEJM199809243391307 · DOI · Paper page
- 10.1016/S0378-4274(01)00329-0 · DOI · Paper page
- 10.1006/bbrc.1993.2135 · DOI
- 10.1016/0301-4622(90)80012-V · DOI · Paper page
- 10.1111/j.1432-1033.1987.tb13649.x · DOI
- 10.1161/01.CIR.0000093196.59829.DF · DOI · Paper page
- 10.1161/01.CIR.0000055318.09997.1F · DOI · Paper page
- 10.1016/0921-8734(92)90021-G · DOI · Paper page
- 10.1002/humu.1380030107 · DOI · Paper page
- 10.1016/0076-6879(95)60134-1 · DOI
- 10.1097/00002030-200211080-00009 · DOI · Paper page
- 10.1126/science.2711184 · DOI · Paper page
- 10.1016/S0076-6879(96)64038-5 · doi:10.1016/s0076-6879(96)64038-5
- 10.1016/S0076-6879(96)64032-4 · DOI
- 10.1038/sj.sc.3100660 · DOI
- 10.1161/01.RES.82.12.1298 · DOI · Paper page
- 10.1124/pr.56.2.6 · DOI · Paper page
- 10.1200/JCO.1999.17.10.3333 · DOI · Paper page
- 10.1016/0163-7258(90)90088-J · DOI · Paper page
- 10.1161/01.RES.86.9.960 · DOI · Paper page
- 10.1016/0921-8734(92)90028-N · DOI
- 10.1126/science.6093249 · DOI · Paper page
- 10.1093/mutage/18.1.25 · DOI
- 10.1093/hmg/11.3.317 · DOI
- 10.1097/00001573-200105000-00008 · DOI
- 10.1053/pcad.2003.3b · DOI
- 10.1002/(SICI)1097-4598(200001)23:1<80::AID-MUS10>3.0.CO;2-V · doi:10.1002/(sici)1097-4598(200001)23:1<80::aid-mus10>3.0.co;2-v
- Childs AC, 2002, Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl‐2:Bax ratio, Cancer Res, 62, 4592
- 10.1016/S0006-2952(01)00865-6 · doi:10.1016/s0006-2952(01)00865-6
- 10.2165/00002018-200022040-00002 · DOI · Paper page
- 10.1016/S0005-2728(99)00011-0 · DOI · Paper page
- 10.2165/00003495-199300452-00005 · DOI
- Torti FM, 1986, Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy, Cancer Res, 46, 3722
- Borchmann P, 1997, Idarubicin: a brief overview on pharmacology and clinical use, Int J Clin Pharmacol Ther, 35, 80
- 10.1200/JCO.1993.11.7.1264 · doi:10.1200/jco.1993.11.7.1264
- 10.1007/BF00252973 · doi:10.1007/bf00252973
- 10.1007/BF00262774 · DOI
- 10.1038/290457a0 · DOI · Paper page
Cited by
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 569
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Clair, D. K. (2007) · Molecular Interventions · doi:10.1124/mi.7.3.6 · Cited by 387
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4795 · Cited by 329
Kalyanaraman, B. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101394 · Cited by 326
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Zhang, Y., Yu, Z., Jiang, D., Liang, X., Liao, S., Zhang, Z., Yue, W., Li, X., Chiu, S.-M., Chai, Y.-H., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.009 · Cited by 268
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Metadata
- Authors
- Lebrecht, D., Kokkori, A., Ketelsen, U., Setzer, B., & Walker, U. A.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2005-11-08
- Volume
- 207
- Issue
- 4
- Pages
- 436-444
- ISSN
- 0022-3417
- 1096-9896
- Cited by
- 133
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.